UroMed's Reliance recommended for FDA approval:
This article was originally published in Clinica
Executive Summary
UroMed's Reliance urinary control insert has been recommended for US FDA approval by an FDA advisory panel. The intra- urethral device is designed for managing female stress incontinence and is available in seven European countries. UroMed, which is based in Needham, Massachusetts, estimates that urinary incontinence affects 26 million women in the US, Japan and Europe each year.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.